UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 19, 2025**

QUANTUM-SI INCORPORATED

(Exact name of registrant as specified in its charter)

Delaware	**001-39486**	**85-1388175**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

29 Business Park Drive **Branford, Connecticut**	**06405**
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: **(866) 688-7374**

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Class A common stock, par value $0.0001 per share	QSI	The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share	QSIAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

From time to time, Quantum-Si Incorporated (the "Company") presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On November 19, 2025, the Company gave a presentation at its Investor & Analyst Day. The presentation slides and a replay of the webcast are available on the "Investors" section of the Company's website at https://ir.quantum-si.com. This presentation is also furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The furnishing of the information in this Item 7.01 and Exhibit 99.1 is not intended to, and does not, constitute a determination or admission by the Company that the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company or any of its affiliates.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Investor & Analyst Day Presentation of Quantum-Si Incorporated dated November 19, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

QUANTUM-SI INCORPORATED

By: /s/ *Jeffry Keyes*
Name: Jeffry Keyes
Title: Chief Financial Officer

Date: November 20, 2025

QUANTUM SI

Quantum Si

Investor & Analyst Day

November 19, 2025

Investor Day Agenda

Jeff Hawkins, CEO	**Tackling the Complexity of the Proteome**	10:00–10:10 AM
Todd Rearick, CTO	**Proteus Program Update and Long-term Technology Roadmap**	10:10–10:40 AM
John Vieceli, CPO	**The Path to Detecting All 20 Amino Acids**	10:40–11:05 AM
Brian Reed, Head of Research	**Post-translational Modification Analysis Solutions**	11:05–11:25 AM
Jeff Hawkins, CEO	**The Road to Proteus Launch**	11:25–11:45 AM
Management	**Q&A Session**	11:45 AM–Noon

Proteins Are the Core of Biological Discoveries Across Many End Markets

Proteome Complexity



The Study of Proteoforms Extends to Many Disease Areas and Thousands of Unique Proteins

Affinity-based methods cannot scale to this complexity

Complete coverage of the proteome would require hundreds of thousands or more unique, site-specific affinity reagents

Only single-molecule protein sequencing can tackle this complexity



Human Proteoform Project: https://www.science.org/doi/10.1126/sciadv.abk0734

Proteoforms Are Not Limited to a Single PTM Type

They are far more diverse, even within a single protein





Source: *J. Proteome Res.* 2025, 24, 6, 2916–2925

Proteoforms Also Include Single Amino Acid Variants, Which Can Be Critical to Understanding Disease



Adapted from Ramadas N and Sparkenbaugh EM (2023). The APC-EPCR-PAR1 axis in sickle cell disease. *Front. Med.* 10:1141020.

Specialized Platforms With High Capital Costs Limit Adoption Outside of Core Labs in Proteomics

- **Many specialized platforms** needed to fully interrogate the proteome
- **Technical tradeoffs** when selecting between the breadth of protein coverage and depth of insights
- **High capital costs** with the top end instruments costs $1M or more each
- **Manual laboratory and data analysis workflows** limit the number of laboratories capable of performing proteomics

Moving Beyond the Core Lab: Proteus Will Enable Deep Protein Analysis and Accelerate the Field of Proteomics

Single-molecule protein sequencing will be the most versatile technology in proteomics — single AA variants, broad PTM coverage, and protein-agnostic

Automation simplifies laboratory workflow, increases throughput, and minimizes the need for specialized staff

Affordable, allowing any lab — anywhere — to be a proteomics core lab

Themes of Today's Presentations

Proteus performance data and long-term technology roadmap

The path to detecting all 20 amino acids

A diverse set of tools to enable generalizable PTM analysis

Road to Proteus launch and 2026 milestones

QUANTUM SI

Proteus™
Program Update

Proteus Next-generation Architecture

Platinum® Pro + 2M Chip

- Integrated semiconductor consumable
- Benchtop instrument with manual workflow

Proteus™ + KinetIQ™ Array

- Simple, passive consumable
- Benchtop instrument with imaging system
- Workflow automation

KinetIQ™ Array

Simple, passive consumable

- Low-cost fused silica die
- 80M wells per device
- Architecture scales to billions of wells



Simple packaging

- Inexpensive plastic assembly
- Four flow cells, each with 20M wells
- Features to support automation

Proteus Instrument

Optical module

- High-performance custom optical design
- High resolution and large field of view
- Supports simple passive consumable

Liquid handling

- Full workflow automation
- More advanced workflows, deeper insights


Proteus Program Status
Key technical risks retired or substantially reduced
Critical system components matured through several prototypes
Integrated system design complete — building first systems now
QUANTUM SI
15

Sequencing Workflow Automation is More Reproducible Than Current Manual Workflow

Integrated System Liquid Handling

Prototype Liquid Handling Subsystem Data



- Same architecture as integrated product design
- Entire sequencing workflow fully automated

KinetIQ Array Fabrication and Post-processing Processes are Established



Wafer fabrication process established

Well structure optimized

Product intent die size + geometry

Wafer-scale post-processing

Efficient packaging process

Data from Prototype Imaging System and New Dyes Fully Validates Transition from Lifetime to Color Ratio

Fully Functional Imaging System

- Same architecture as product design
- Commercial off-the-shelf components
- Product-intent image sensors
- Reduced field of view

Proven Color Channel Detection



- New color-space dye set
- Demonstrated up to 8 dyes
- Room for more if needed

Successful Dynamic Sequencing Runs Completed in Q3



Substantial de-risking new system elements

Consumable, dyes, optical system, software

Proteus Has Superior Sequencing Output Per Well Compared to Platinum

Alignments per well (normalized to Platinum)



Proteus routinely produces more alignments with the same number of wells

Long-read fraction (normalized to Platinum)



Proteus produces more long alignments compared to Platinum

Proteus Consistently Sequences Deep into Peptides

- **Unique capability for long-range structural information**
- **Access to PTMs and variants deep into reads**
- **Sequencing depth expected to continue to improve with increased coverage and further optimization**

Proteus Has Superior SNR and Short Pulse Detection Compared to Platinum

Better SNR

- More high-quality alignments
- Better accuracy
- More sensitive for PTMs and variants



More sensitive short pulse detection

- Increased motif coverage with the same binders
- Software not optimized for improved data



Proteus Sequencing Performance is on Track to Far Exceed Platinum at Launch

Proteus data is already superior to Platinum data

Data generated to date is without optimization

Current algorithms | Current V4 binder set | Current cutters and chemistry

Additional improvements expected before launch

Integrated System in Development

First Integrated System Expected 1Q26

- Full integration of imaging and workflow automation
- Product-like consumables
- Full field of view supporting 20M wells

Proteus Program Summary

- **Transition to new architecture is proven — team is executing towards product launch for YE2026**
- **Proteus architecture shows significant improvement over Platinum in the quantity and quality of sequencing output**
- **Platform launch is aligned with improvements in biochemistry and library prep that will drive additional performance gains**

QUANTUM SI

Long-term Technology Roadmap

Proteus Architecture Supports Our Long-term Platform Roadmap Requirements

Consumable architecture scales to billions of wells

10× scaling from assay improvements alone

Future instruments capable of up to 10B reads



Super Poisson Loading Increases Sequencing Output per Run by Approximately 3×



Poisson Loading

- Peptides randomly loaded into wells
- Maximum single-molecule loading ~36%
- 64% of wells are empty or multiply-loaded



Super Poisson Loading

- Peptides are loaded in a way that prevents multiple loading
- Only one peptide can be loaded in most wells

Faster Sequencing Roadmap + Field Upgrades Could Drive Output Up to 320M and Increase Samples per Run

Proteus (**80M**) | **160M** | **320M** | Proteus Plus (**up to 320M**)

Sequencing time reductions allow more chips to be run in same timeframe as original 80M

Upgrade to drawer/stage and consumable to increase chips/run

The Path to Billions of Reads Requires Controlled Cutting

- Cutting happens randomly
- Residue duration is not uniform
- Time/residue is slower on average
- Controlled cutting would define the amino acid boundaries + enable a scanning system

Current Sequencing Chemistry



We Have Successfully Demonstrated a Controlled Cleavage Version of Our Sequencing Chemistry

- Enables scanning system
- Amino acid boundaries are known
- Residue duration is controlled and uniform
- Time/residue is much faster on average



Combining Controlled Cleavage with High-speed Scanning Scales the Architecture to Billions of Reads

Proteus 2.0 can incorporate high-speed scanning and microfluidic delivery system

Scanning system enables billions of reads

Multiple imaging locations within one flow cell

Efficient usage of device area

Enabled by controlled cleavage chemistry



Multiple imaging regions per flow cell

QUANTUM SI

The Path to Detecting all 20 Amino Acids

John Vieceli, Chief Product Officer
November 19, 2025


Vision
Develop a set of N-terminal amino acid recognizers for twenty canonical amino acids on Proteus™

QUANTUM SI

Recognizer Roadmap

Sequencing Technology Overview

Recognizers bind amino acids in sequence

Recognition events produce kinetic signatures





Amino Acid Recognizers in Sequencing Kit V4

Recognition for 14 of 20 amino acids using 6 recognizers



Software Improvements Enable More Amino Acids

Q4 software release with Library Prep Kit V3 will increase to 15 amino acids





Path to 20 Amino Acids with 8 Recognizers

Detection of 18 amino acids demonstrated with campaigns for C and T underway



Recognizer Roadmap Supported on Proteus

Intensity and color ratio space supports 8+ dyes

Eight dyes have been demonstrated on Proteus prototype system

Additional dye space available if necessary



QUANTUM SI

Recognizer Development Pipeline

Recognizer Evolutionary Tree

6 recognizers in Sequencing Kit V4 were derived from 4 starting proteins

QSI recognizers
protected by 27 granted patents and applications



Quantum-Si N-terminal Amino Acid Recognizer Data

Binding Data		Structural Data		Kinetic Data	
					
~10^7	~3,500	~800	~40	~100	~300

Labeled amino acid sequence data for binding N-terminal amino acids

AI model refinement

Predicted N-terminal amino acid binder

Protein Databank Mining for N-terminal Binders

Used for scaffold generation and model training





AI Model Refinement Enabled By Academia and Industry


PRESS RELEASE

The Nobel Prize in Chemistry 2024

David Baker

Demis Hassabis

John Jumper

"for computational protein design"

"for protein structure prediction"

They cracked the code for proteins' amazing structures

Ligand message-passing neural network

Meta AI

Evolutionary scale modeling

NVIDIA

GPU hardware acceleration

4× Scale-up of Recognizer Development Pipeline

Utilize AI, rational, and combinatorial design approaches to generate candidates for screening pipeline



X-ray Crystallography with Combinatorial and AI Strategies Yielded the GAS Recognizer



Proline Recognizer from AI and Combinatorial Methods



Summary of the Path to Twenty Amino Acids

Current recognizer pipeline has candidates to go from 14 amino acids with Sequencing Kit V4 to **18 at Proteus launch in 2026**

Recognizer development program is being scaled **4×** to achieve detection of all canonical amino acids in 2026 and **release on Proteus in 2027**

Efforts in artificial intelligence utilize Quantum-Si screening data to refine deep learning and language models, in conjunction with rational and combinatorial design, to **accelerate the pace of recognizer development**

QUANTUM SI

PTM Analysis Solutions

Brian Reed, PhD

Head of Research

Agenda

PTM Solutions on Proteus

1. Advantages of single-molecule detection for PTMs
2. Broad access to PTMs on Proteus
3. PTM applications on the path to Proteus launch

PTMs and Proteoforms are the Next Frontier in Human Health



A post-translational modification (PTM) is a chemical change to an amino acid made *after* a protein has been expressed.

There are hundreds of different types of PTMs. A handful are of high interest in the proteomics due to their high abundance and roles in disease pathways. Examples: phosphorylation, glycosylation, ubiquitination.

PTMs determine actual protein function — making them essential for understanding disease mechanisms and therapeutic targets — but have been difficult to study with current proteomics technology.

Challenge to Detecting PTMs With Existing Technologies

Mass spectrometry

- Quantification difficult
- Ambiguity in modification site assignment
- Multi-site combinations extremely challenging
- Workflow and analytical complexity (limits clinical adoption)

Affinity-based platforms

- Detect proteins but provide no proteoform information

OR

- Need costly site-specific affinity reagents for *every* protein

Advantages of Single-molecule Detection for PTMs

- **Quantitation** straightforward due to direct counting of molecules
- **Direct PTM** site identification
- **Access to multi-site** PTM combinations
- **Simple workflows** for broad PTM proteome coverage; clinical compatibility
- **Universal PTM detection** reagents and assays for ***all*** proteins

Single-molecule Detection Enables Broad PTM Coverage

NGPS unlocks broad and universal access to PTMs with three complimentary approaches | Can be used in combination to address the most challenging needs in PTM detection

Kinetics

PTM detected via kinetic changes at upstream AAs

Pre-recognition

PTM detected with a PTM binder prior to sequencing

Direct NAA detection

PTM detected with an N-terminal PTM binder during sequencing

Complete AA coverage and deep peptide sequencing will enable very high proteome-wide PTM coverage **on Proteus for all three methods**

Kinetic Detection of PTMs

- **Kinetic response to PTMs** is a universal feature of NAA recognizers—when the chemical makeup of the peptide changes, the kinetics change. No extra reagents or processing steps needed
- **Examples:** phospho-, methyl-, acetyl-, oxidation, citrullination
- **Customers are using** to dissect complex PTM arrangements that are ambiguous or inaccessible with MS



PD = 2.1s

PD = 0.84s

Pre-recognition of PTMs

- **PTM detection at any position** regardless of peptide length
- **Parallel detection** of multiple PTMs
- **E.g., Pan-phospho kit:** Comprehensive detection of pS/pT/pY in one assay
- **Extreme sensitivity** to PTM stoichiometry due to the clear pulsing pattern from PTM recognition



Direct N-terminal Detection of PTMs

Direct NAA detection

- **N-terminal PTM recognizer** included in sequencing assay
- **Can be standard** NAA recognizer or custom
- **Enables reference-free/*de novo*** PTM discovery
- **Suitable for very complex** sequence contexts and multisite PTM/variant arrangements



Kinetics: Influence of Downstream pY on NAA Recognizers

Unmodified peptide



pY modified peptide



How pY influences recognizer kinetics in this peptide

- **R pulse duration** decreases from 1.3 to 0.5 sec.
- **L pulse duration** increases from 2.5 to 3.5 sec.
- **Y** is no longer recognized

Used to detect tropomyosin proteoforms



https://pubs.acs.org/doi/pdf/10.1021/acs.jproteome.4c00978

Kinetics: Influence of Citrulline on NAA Recognizers

Arginine citrullination is challenging to detect by mass spec because of the negligible increase in mass (0.984 Da)



How citrulline influences recognizer kinetics in this peptide

- **F pulse duration** decreases from 3.49 to 2.65 seconds
- **L pulse duration** increases from 0.48 to 1.0 seconds
- **R** is no longer recognized

Kinetics: Multiple Kinetic Parameters Inform PTM Detection



Citrulline and other PTMs influence *multiple* kinetic parameters

- **Pulse duration:** the lifetime of the recognizer-NAA bound state
- **Interpulse duration:** the time between recognizer binding events
- **Recognition segment (RS) duration:** the time between NAA cleavage events

Pre-recognition: pY Detection at *Any* Peptide Location

An anti-phosphotyrosine antibody detects phosphotyrosine at any peptide location — N-terminal, internal, and C-terminal linker adjacent — independent of sequence context



Pre-recognition: Carna Biosciences Kinase Panel

Phosphorylation is a key determinant of activity for protein kinases used in drug discovery applications | Pre-recognition identifies phosphotyrosine in protein-tyrosine kinase 2-beta (PYK2B) and other important kinases



Direct NAA Detection: Methionine Oxidation

The NQM recognizer directly detects N-terminal methionine sulfoxide at position Met91 in IKBA



We Have a Clear Path to Broad PTM Coverage on Proteus

Recognizer development

Recognizers for all 20 amino acids will ensure maximum protein coverage and kinetic information available for PTM detection with all three methods

Higher output on Proteus

Enables deeper and more sensitive PTM detection and multiplexed panel-based solutions

Artificial intelligence

For data analysis to fully extract the massive volume of kinetic information in our NGPS output for PTM and variant detection and quantitation

PTM access with three methods

Three complimentary approaches that can be used in combination ensure access to the broadest range of PTMs anywhere in the proteome

QUANTUM SI

The Road to Proteus Launch

From Platinum to Proteus — Market Learnings Inform Proteus Requirements and Commercial Strategy

General technology first; **defined applications** second

Sample prep-agnostic

Broad marketing to all segments at launch

Defined applications first; **general technology** second

***Sample-to-report* workflows** for high-value applications

Focused launch — achieve application depth in target segment(s)

Amino acid coverage ▲ **Reliability ▲** **Sample input ▼**

Sequencing output ▲ **Consumable COGs ▼**

The Customer Data is Clear

Researchers need a breadth of capabilities to answer their biological questions

Number of PTMs Required



PLATINUM PIONEER GRANT PROGRAM

More than 50 detailed study proposals submitted by prospective customers

>50% require three or more types of protein analysis applications

Detection of two or more PTMs is required in >65% of cases

Number of Unique Applications



A Look Inside an Academic Medical Center



- Wide range of application interests
- Limited infrastructure
- Lower utilization

- Many technologies in use in one lab
- Significant infrastructure
- High utilization potential

- Targeted applications; many involve PTMs
- Value automation
- High utilization potential

- Defined application content; *sample-to-report* workflows
- Automation is key
- High utilization potential given repeat sample testing

Platinum Case Study — The Academic Medical Center



Good value prop but most users are low-utilization

Limited to reflex testing downstream of mass spec

Adoption limited by current technology capabilities

Not accessible with Platinum Pro

The Increased Sequencing Output and Lower Costs of the Nanowell Array is Broadly Enabling

More samples per run with 40× the output per consumable compared to Platinum Pro

Deep analysis of a single sample to address complex mixtures or rare events like variants or PTMs

Multiplexing samples to achieve higher throughput and lower costs per sample for cost sensitive applications like protein ID



Accelerating the Core Sequencing Technology and Analytics to Unlock the Highest-value Applications

Robust PTM detection and multi-PTM profiling

Sequencing of variable regions of antibodies

Single-amino acid variant detection

Biothreat detection and surveillance

Proteus Automation Greatly Simplifies the Sequencing Workflow and Makes New Lab Startup Even Easier

Over 30 individual reagent tubes to handle to process four samples

Over 100 pipetting steps per sample

A single reagent module per run — simply unbox and load

Pipette your sample(s) into the cartridge and hit *Run*

Building a Partner Ecosystem to Accelerate Application Development + Deliver *Sample-to-report* Workflows

New Industry Partnerships in PTMs and Ultra-low-abundance Protein Panels

- Carna Biosciences is a leading provider of assay-grade kinase proteins to biopharma for drug discovery and profiling
- Carna Biosciences is evaluating the use of QSI technology to assess and validate phosphorylation profiles of kinases
- Collaboration presents the potential to leverage the complementary strengths and global reach of both organizations

SIENA • QUANT™

- Siena Quant™ is a SISCAPA Holdings Company — experts in the field of sample enrichment for proteomics
- Siena Quant is enabling the quantitation of ultra-low-abundance biomarkers that have been historically unreliable to measure
- QSI and Siena Quant will collaborate to develop sample-to-report workflows for customers to accurately measure clinically relevant biomarker panels

Proteus Will Increase the Depth of Penetration in Academic Medical Centers Compared to Platinum



Basic Research Lab	Core Lab	Translational Lab	Clinical Lab
Single-molecule protein sequencing will remain a useful tool for basic research	High-value application capabilities + increased throughput = first-line platform	Expanded PTM capabilities + high-value targeted panels + automation	Automation + sample-to-report workflows opens this lab for Proteus

Proteus Will Enable Single-molecule Protein Sequencing Across a Broad Range of End Markets

Milestones on the Path to Proteus Launch in 2026



QSI is Well-positioned to Build Upon Our First-to-market Advantage and Extend Our Leadership into the Future

Grow user base with Platinum Pro and develop the market for Proteus launch

Execute on development roadmap to deliver a compelling Proteus launch

Build a partner ecosystem to accelerate application development + deliver *sample-to-report* workflows

Extend our technology lead through best-in-class R&D innovation + execution